City Therapeutics (Nasdaq: CTY), a clinical-stage RNAi company, closed its upsized IPO raising $230M at $18 per share. Read ...
Disc Medicine's bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for EPP, setting up an NDA ...
Rapport Therapeutics' RAP-219 met primary and secondary endpoints in a Phase II bipolar mania trial, cutting YMRS scores. See results and Phase III plans.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results